Clinical Trial Update: A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating monosialic gangliosides to prevent neurotoxicity from albumin-bound paclitaxel in early breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Monosialic gangliosides

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Early Breast Cancer | Phase 2 | Status: COMPLETED